Targeting transgene to the heart and liver with AAV 9 by different promoters
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Summary: Adeno‐associated virus (AAV) has become one of the most promising gene transfer tools for gene therapy. This work aims to evaluate tropism, gene transfer efficiency and safety of AAV 9 vectors produced with recombinant baculovirus (rB ac)‐based system. AAV 9‐CMV‐GFP and AAV 9‐CBA‐GFP were produced using a rB ac system, 1 × 10 11 particles of each vectors were administered intravenously (i.v.) into mice and animals were killed at 1, 2, 3, 4, 5 and 8 weeks after administration. The GFP expression in different organs was analyzed by fluorescence imaging and Western blot. Viral genomic quantities were measured using qPCR. In vitro transduction efficiency of AAV 9 vectors in primary cardiomyocytes and hepatocytes was determined by flow cytometry. Toxicity of AAV 9 vectors was evaluated by determining certain cardiac and liver injury biomarkers and renal function test in vivo and TUNEL analysis in vitro. The data showed that AAV 9 viral particles packaged by the rB ac system were fully functional in vivo and in vitro. The CMV promoter predominantly induced higher cardiac GFP transgene expression and DNA copy numbers while the CBA promoter resulted in robust GFP expression and high vector DNA copy numbers in mouse liver, both in a time‐dependent increased manner. Such distinct preferential effects were also observed in the heart and liver as early as 3 and 5 days after co‐infection. Both the AAV 9‐CMV and AAV 9‐CBA viral packages did not induce heart, liver and renal damage and cell apoptosis. These results indicated that AAV 9‐CMV can efficiently and safely direct cardiac gene transfer, whereas AAV 9‐CBA is preferential for liver gene delivery.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Systemic delivery of genes to striated muscles using adeno-associated viral vectors
Gregorevic, P., Blankinship, M. J., Allen, J. M., Crawford, R. W., Meuse, L., Miller, D. G., Russell, D. W., & Chamberlain, J. S. (2004) · Nature Medicine · doi:10.1038/nm1085 · Cited by 620
Inagaki, K., Fuess, S., Storm, T. A., Gibson, G. A., Mctiernan, C. F., Kay, M. A., & Nakai, H. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.014 · Cited by 610
Gray, S. J., Foti, S. B., Schwartz, J. W., Bachaboina, L., Taylor-Blake, B., Coleman, J., Ehlers, M. D., Zylka, M. J., McCown, T. J., & Samulski, R. J. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.245 · Cited by 420
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
Pacak, C. A., Mah, C. S., Thattaliyath, B. D., Conlon, T. J., Lewis, M. A., Cloutier, D. E., Zolotukhin, I., Tarantal, A. F., & Byrne, B. J. (2006) · Circulation Research · doi:10.1161/01.res.0000237661.18885.f6 · Cited by 406
Salva, M. Z., Himeda, C. L., Tai, P. W., Nishiuchi, E., Gregorevic, P., Allen, J. M., Finn, E. E., Nguyen, Q. G., Blankinship, M. J., Meuse, L., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300027 · Cited by 232 · cited 1×
“However, such unintended liver transgene expression can be diminished through reducing the dose of recombinant AAV9 vector,(7) using cardiac-specific promoters(10,23) or microRNA-122 target sequences.(24) Interestingly, although the liver had higher DNA copy numbers, the heart had the highest GFP expression levels amo…”
BackgroundQiao, C., Yuan, Z., Li, J., He, B., Zheng, H., Mayer, C., Li, J., & Xiao, X. (2011) · Gene Therapy · doi:10.1038/gt.2010.157 · Cited by 163 · cited 1×
“Recombinant AAV9 vectors purchased from Virovek (Hayward, CA, USA), were produced with the rBac-based system in SF9 cells as described previously.(17,28) rAAV9 vectors were packaged with single-stranded DNA containing enhanced green fluorescent protein (GFP) gene, which was driven by either the human cytomegalovirus (…”
MethodBeltran, W. A., Boye, S. L., Boye, S. E., Chiodo, V. A., Lewin, A. S., Hauswirth, W. W., & Aguirre, G. D. (2010) · Gene Therapy · doi:10.1038/gt.2010.56 · Cited by 96 · cited 1×
“promoter (a CMV enhancer/chicken b-actin promoter hybrid) yields ubiquitously robust transgene expression.(15) Many studies have focused mostly on identifying potent AAV serotypes for cardiac or liver gene transfer but lack side-by-side comparative study on AAV9 gene transfer driven by CMV and CBA promoter in the mous…”
Background
Cited by
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety · doi:10.1007/s40264-021-01107-6 · Cited by 119
Characterization of AAV vectors: a review of analytical techniques and critical quality attributes
Kontogiannis, T., Braybrook, J., McElroy, C., Foy, C., Whale, A. S., Quaglia, M., & Smales, C. M. (2024) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2024.101309 · Cited by 57
Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy
Gong, Y., Berenson, A., Laheji, F., Gao, G., Wang, D., Ng, C., Volak, A., Kok, R., Kreouzis, V., Dijkstra, I. M., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.079 · Cited by 45
Alternative strategies in cardiac preclinical research and new clinical trial formats
Kreutzer, F. P., Meinecke, A., Schmidt, K., Fiedler, J., & Thum, T. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab075 · Cited by 36
“jection of a plasmid or using promiscuous viral vector such as Sendai virus into embryos,(33,34) or tissue-specific, such as AAV9 for heart specific introduction of transgenes.(35) Cre recombinase systems even introduce”
Background
Metadata
- Authors
- Chen, B., He, C., Chen, X., Pan, S., Liu, F., Ma, X., Li, X., Gai, M., Tao, J., Ma, Y., Yang, Y., & Gao, X.
- Venue
- Clinical and Experimental Pharmacology and Physiology
- Publisher
- Wiley
- Published
- 2015-09-15
- Volume
- 42
- Issue
- 10
- Pages
- 1108-1117
- ISSN
- 0305-1870 (ISSN-L)
- 1440-1681
- OpenAlex
- W1907611889
- Cited by
- 52
- References
- 7
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting transgene to the heart and liver with AAV 9 by different promoters. https://app.cochat.ai/papers/10.1111/1440-1681.12453
- The paper
- Chen, B., He, C., Chen, X., Pan, S., Liu, F., Ma, X., Li, X., Gai, M., Tao, J., Ma, Y., Yang, Y., & Gao, X. (2015). Targeting transgene to the heart and liver with AAV 9 by different promoters. Clinical and Experimental Pharmacology and Physiology. https://doi.org/10.1111/1440-1681.12453
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.